Total for the last 12 months
number of access : ?
number of downloads : ?
ID 117584
Author
Takei, Minori Tokushima University
Keywords
genome-wide association study
dysgeusia
anti-cancer drug
hematopoietic tumor
single nucleotide polymorphism
Content Type
Journal Article
Description
Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient’s QOL, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia using associated single nucleotide polymorphisms (SNPs). GWAS was conducted on 76 patients admitted to the Department of Hematology, Tokushima University Hospital. Using Sanger sequencing for 23 separately collected validation samples, the top two SNPs associated with the development of dysgeusia were determined. GWAS identified rs73049478 and rs41396146 SNPs on the retinoic acid receptor beta (RARB) gene associated with dysgeusia development due to the administration of anti-cancer drugs. Evaluation of the two SNPs using 23 validation samples indicated that the accuracy rate of rs73049478 was relatively high (87.0%). Thus, the findings of the present study suggest that the rs73049478 SNP of RARB can be used to predict the onset of dysgeusia caused by the administration of anti-cancer drugs.
Journal Title
Biological and Pharmaceutical Bulletin
ISSN
13475215
09186158
NCID
AA11696048
AA10885497
Publisher
The Pharmaceutical Society of Japan
Volume
45
Issue
1
Start Page
114
End Page
117
Published Date
2022-01-01
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Pharmaceutical Sciences
Medical Sciences
University Hospital